Rabeprazole: Clinical Trials

82 trials of Rabeprazole, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

76 completed, 3 recruiting, 1 active not recruiting, 1 terminated. 82 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 182Completed 76, Recruiting 3, Active not recruiting 1, Terminated 1, Unknown 1
Phase 23Completed 2, Recruiting 1

Follow Rabeprazole: new trials by email Literature Review of Rabeprazole trials Research Report on Rabeprazole

Trials (filtered) newest first · largest first

All 82 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Assessing the Effect of a Proton Pump Inhibitor on the Pharmacokinetics of DZD8586 in Healthy Participants (TAI-SHAN21)
DZD8586, Rabeprazole - Healthy
Phase 1RecruitingDizal Pharmaceuticals262026-10-232026-11-06
A Study of RO7890597 in Healthy Adult Volunteers
RO7890597, Placebo, Rabeprazole - Healthy Volunteers
Phase 1RecruitingGenentech, Inc.1392026-08-282026-11-17
A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules
HMPL-760, Rabeprazole and HMPL-760 - Healthy Participants
Phase 1CompletedHutchmed242026-06-302026-09-18
A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults
PF-08049820, Rabeprazole - Healthy Adults, Healthy
Phase 1CompletedPfizer242026-05-132026-10-01
A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants
ZN-A-1041 Formulation 1, ZN-A-1041 Formulation 2, Rabeprazole - Healthy Volunteers
Phase 1CompletedGenentech, Inc.242025-11-212026-05-11
A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Healthy Chinese Adults.
PF-08049820, Rabeprazole - Healthy Adults
Phase 1CompletedPfizer182025-11-032026-09-09
A Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Pharmacokinetics of VRN110755
VRN110755, Rabeprazole - Healthy
Phase 1CompletedVoronoi, Inc252025-08-272026-05-08
Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat
Nirogacestat, Nirogacestat and Famotidine, Nirogacestat and Rabeprazole - Healthy
Phase 1CompletedSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany242025-08-212026-05-08
Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid
LY4100511, Rabeprazole - Healthy Participants
Phase 1TerminatedEli Lilly and Company12025-04-082026-09-09
Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib
Saruparib, Digoxin, Furosemide - Advanced Solid Malignancies
Phase 1Active not recruitingAstraZeneca412025-03-252026-10-01
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
DCC-3009, Rabeprazole - Gastrointestinal Stromal Tumor (GIST)
Phase 1 / Phase 2RecruitingDeciphera Pharmaceuticals, LLC1552024-12-102026-11-12
Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants
BMS-986365, Rabeprazole - Healthy Participants
Phase 1CompletedCelgene1022024-05-282025-03-06
Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers
ZE50-0134 or placebo, Rabeprazole 20 mg, Itraconazole (200 mg) - Healthy
Phase 1CompletedLomond Therapeutics Holdings, Inc.1042024-05-212025-12-05
A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants
BIIB122, Rabeprazole - Healthy Volunteer
Phase 1CompletedBiogen182024-02-122024-07-19
A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)
Embibatinib, Rabeprazole, Midazolam - Healthy
Phase 1CompletedTerns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)1962023-12-212026-10-22
A Study to Learn How a Medicine That Reduces Stomach Acid Affects the Level of Sisunatovir in the Blood of Healthy Adults.
Sisunatovir, Rabeprazole 40 mg, Sisunatovir suspension - Healthy
Phase 1CompletedPfizer402023-11-032025-04-24
A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants
PC14586, Rabeprazole, Famotidine - Healthy Volunteers
Phase 1CompletedPMV Pharmaceuticals, Inc282023-09-192024-11-13
Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers
ZE46-0134 or placebo, Rabeprazole, 20mg oral, Itraconazole (200 mg) - AML
Phase 1CompletedLomond Therapeutics Holdings, Inc.1122023-07-282025-12-09
A Study of Maribavir Pediatric Formulation in Healthy Adult Participants
Maribavir Commercial Tablet Formulation, Maribavir Pediatric Powder-for-oral Suspension Formulation, Rabeprazole - Healthy Volunteers
Phase 1CompletedTakeda322023-07-252024-09-26
Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant
Camlipixant, Rabeprazole, Rifampin - Cough, Healthy
Phase 1CompletedBellus Health Inc. - a GSK company422023-06-212024-12-04

Showing 20 of 82. Sign in to see all of them.

Conditions studied

Gastroesophageal Reflux (8)  ·  Amyotrophic Lateral Sclerosis (2)  ·  Lymphoma (2)  ·  Neoplasms (2)  ·  Recurrence (2)  ·  Autoimmune Diseases (1)  ·  COVID-19 (1)  ·  Cholangiocarcinoma (1)  ·  Colorectal Neoplasms (1)  ·  Communicable Diseases (1)  ·  Cough (1)  ·  Dermatitis, Atopic (1)  ·  Gastrointestinal Stromal Tumors (1)  ·  Hematologic Neoplasms (1)  ·  Hereditary Sensory and Autonomic Neuropathies (1)

Sponsors

Genentech, Inc. (10)  ·  Pfizer (10)  ·  AstraZeneca (5)  ·  Hutchmed (4)  ·  Eisai Co., Ltd. (3)  ·  Janssen Research & Development, LLC (3)  ·  Addpharma Inc. (2)  ·  Biogen (2)  ·  Bristol-Myers Squibb (2)  ·  Celgene (2)  ·  Haihe Biopharma Co., Ltd. (2)  ·  Hutchison Medipharma Limited (2)  ·  Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2)  ·  Lomond Therapeutics Holdings, Inc. (2)  ·  Mylan Pharmaceuticals Inc (2)

Countries

United States (40)  ·  United Kingdom (10)  ·  China (8)  ·  Australia (4)  ·  Canada (4)  ·  Germany (4)  ·  South Korea (4)  ·  Belgium (3)  ·  France (2)  ·  India (2)  ·  Japan (2)  ·  Netherlands (2)  ·  Poland (2)  ·  Brazil (1)  ·  Bulgaria (1)

Top investigators

James D Carlson, Pharm. D. (2)  ·  Kai Shibata (2)  ·  Scott Holden, M.D. (2)  ·  Seunghwan Lee, M.D.,Ph.D (2)  ·  Youngiun Kim, MD (2)  ·  Ahmed Elshafeey, Ph.D. Pharma (1)

Results publications

PMID 17116123, PMID 23689261, PMID 23980906, PMID 27129014, PMID 27154174, PMID 30536154, PMID 35445718, PMID 37705327, PMID 38359854, PMID 39087871, PMID 39711068, PMID 40077903, PMID 41058119

NIH funding

2017 (4), 2015 (2), 2008 (1), 2018 (1), 2019 (1), 2023 (1)